More recently aflibercept, a soluble decoy construct containing a fusion of VEGFR1 and VEGFR2 ligand binding domains, was shown to inhibit tumor growth in several mouse models of HCC [36]. Here, FLT1 is linked to hepatocellular carcinoma.